Evidence map›Paper›PMID 37686345›Full record

ArticleInternational journal of molecular sciences2023

Improvement of Vascular Insulin Sensitivity by Ranolazine.

Sol Guerra-Ojeda, Adrian Jorda, Constanza Aldasoro, Jose M Vila, Soraya L Valles, Oscar J Arias-Mutis, Martin Aldasoro

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Effects of Ranolazine on Vascular Adrenergic Receptors in Rabbit Aorta.International journal of medical sciences · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sol Guerra-OjedaDepartment of Physiology, University of Valencia, 46010 València, Spain.ORCID 0000-0003-3018-4683
Adrian JordaDepartment of Physiology, University of Valencia, 46010 València, Spain.
Constanza AldasoroDepartment of Physiology, University of Valencia, 46010 València, Spain.
Jose M VilaDepartment of Physiology, University of Valencia, 46010 València, Spain.
Soraya L VallesDepartment of Physiology, University of Valencia, 46010 València, Spain.ORCID 0000-0003-4861-4266
Oscar J Arias-MutisDepartment of Physiology, University of Valencia, 46010 València, Spain.ORCID 0000-0002-7914-743X
Martin AldasoroDepartment of Physiology, University of Valencia, 46010 València, Spain.ORCID 0000-0001-6630-0493
Universitat de València · ES

Funding

University of Valencia. Specific Key 20180268
6 · The paper itself

Abstract

Ranolazine (RN) is a drug used in the treatment of chronic coronary ischemia. Different clinical trials have shown that RN behaves as an anti-diabetic drug by lowering blood glucose and glycosylated hemoglobin (HbA1c) levels. However, RN has not been shown to improve insulin (IN) sensitivity. Our study investigates the possible facilitating effects of RN on the actions of IN in the rabbit aorta. IN induced vasodilation of the abdominal aorta in a concentration-dependent manner, and this dilatory effect was due to the phosphorylation of endothelial nitric oxide synthase (eNOS) and the formation of nitric oxide (NO). On the other hand, IN facilitated the vasodilator effects of acetylcholine but not the vasodilation induced by sodium nitroprusside. RN facilitated all the vasodilatory effects of IN. In addition, IN decreased the vasoconstrictor effects of adrenergic nerve stimulation and exogenous noradrenaline. Both effects were in turn facilitated by RN. The joint effect of RN with IN induced a significant increase in the ratio of p-eNOS/eNOS and pAKT/AKT. In conclusion, RN facilitated the vasodilator effects of IN, both direct and induced, on the adrenergic system. Therefore, RN increases vascular sensitivity to IN, thus decreasing tissue resistance to the hormone, a key mechanism in the development of type II diabetes.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceAdrenergic AgentsAnimalsAorta, AbdominalRabbitsRanolazineVasodilator AgentsAdrenergic AgentsRanolazineVasodilator Agentsadrenergic systeminsulinnitric oxideranolazinevascular

Identifiers

PMID37686345
PMCPMC10487645
OpenAlexW4386325542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.